Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03297398 · ClinicalTrials.gov registry record · Phase 2
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
A Phase 2 study, sponsored by OPKO Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT03297398 is a Phase 2 study that was terminated before completion, run by OPKO Health. The registered enrollment target is 114 participants.
The verdict
NCT03297398, a Phase 2 study, was terminated before completion, sponsored by OPKO Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
Interventions
- OTHER Placebo
- DRUG Group-1 (15mg, OPK-88004)
- DRUG Group-2 (25 mg,OPK-88004)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2019-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03297398
The ClinicalTrials.gov registry entry for NCT03297398 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03297398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03297398 about?
NCT03297398 is a clinical study titled "Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)". This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
What is the current status of trial NCT03297398?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2018-02-21. Estimated completion is 2019-06-10.
What interventions are being tested in trial NCT03297398?
The interventions under investigation include: Placebo (OTHER), Group-1 (15mg, OPK-88004) (DRUG), Group-2 (25 mg,OPK-88004) (DRUG).
Who is sponsoring clinical trial NCT03297398?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.